CARDIFF ONCOLOGY, INC. Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments
CARDIFF ONCOLOGY, INC. (CRDF) reported Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-06.
Discontinued › Income Statement › Other Income
us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2019-03-06
- CARDIFF ONCOLOGY, INC. available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for the quarter ending 2018-12-31 was $0.00.
- CARDIFF ONCOLOGY, INC. available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for the quarter ending 2018-09-30 was $0.00.
- CARDIFF ONCOLOGY, INC. available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for the quarter ending 2017-12-31 was $0.00.
- CARDIFF ONCOLOGY, INC. available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for the quarter ending 2017-09-30 was $0.00.
- CARDIFF ONCOLOGY, INC. available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for fiscal 2018 was $0.00.
- CARDIFF ONCOLOGY, INC. available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for fiscal 2017 was -$6.40K.
- CARDIFF ONCOLOGY, INC. available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for fiscal 2016 was $0.00.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments 3 month | Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments 6 month | Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments 9 month | Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $0.00 derived: sum of 2 quarters · filed 2019-03-06 | $0.00 10-K · filed 2019-03-06 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | ||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-03 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $0.00 derived: sum of 2 quarters · filed 2019-03-06 | -$6.40K 10-K · filed 2019-03-06 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$6.40K 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | -$6.40K 10-Q · filed 2018-08-03 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $0.00 derived: sum of 2 quarters · filed 2018-02-26 | $0.00 10-K · filed 2018-02-26 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $0.00 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |